Scynexis will pit a new class of antifungals against yeast infections — and it won't come cheap

Nicole DeFeudis

Editor

The FDA ushered in a new class of triterpenoid antifungals this week, giving Scynexis the OK for its oral ibrexafungerp — a non-azole treatment the company …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Scynexis will pit a new class of antifungals against yeast infections — and it won't come cheap

Nicole DeFeudis

Editor

Sign up to read this article for free.

Novartis turns to BioAge for new targets based on longevity and exercise

Updated: Flagship gene therapy startup Ring Therapeutics nearly halves workforce as CEO departs

Post-Hoc: Biosecure is dead. Long live Biosecure?

US spent $450B on drugs last year, CMS says, with new obesity and diabetes drugs adding to total

Novartis, AbbVie and PhRMA secure 340B court win in West Virginia

Merck’s long-awaited obesity move is an oral GLP-1 from China

Scynex­is will pit a new class of an­ti­fun­gals against yeast in­fec­tions — and it won't come cheap

Nicole DeFeudis

Editor

Sign up to read this article for free.

more like this

No­var­tis turns to BioAge for new tar­gets based on longevi­ty and ex­er­cise

Up­dat­ed: Flag­ship gene ther­a­py start­up Ring Ther­a­peu­tics near­ly halves work­force as CEO de­parts

Post-Hoc: Biose­cure is dead. Long live Biose­cure?

US spent $450B on drugs last year, CMS says, with new obe­si­ty and di­a­betes drugs adding to to­tal

No­var­tis, Ab­b­Vie and PhRMA se­cure 340B court win in West Vir­ginia

Mer­ck’s long-await­ed obe­si­ty move is an oral GLP-1 from Chi­na

Scynexis will pit a new class of antifungals against yeast infections — and it won't come cheap

Novartis turns to BioAge for new targets based on longevity and exercise

Updated: Flagship gene therapy startup Ring Therapeutics nearly halves workforce as CEO departs

Post-Hoc: Biosecure is dead. Long live Biosecure?

US spent $450B on drugs last year, CMS says, with new obesity and diabetes drugs adding to total

Novartis, AbbVie and PhRMA secure 340B court win in West Virginia

Merck’s long-awaited obesity move is an oral GLP-1 from China